SPIN cohort

Brain Metabolism in Alzheimer’s Disease Associated with Down Syndrome: New Findings with FDG-PET

by
Regional Brain Metabolism across the Alzheimer's Disease Continuum in Down Syndrome

Down syndrome (DS) is a genetic form of Alzheimer’s disease (AD). Due to the overexpression of the APP gene on chromosome 21, nearly all individuals with DS develop AD-related pathological changes and dementia secondary to this disease. Brain metabolism, measured using fluorodeoxyglucose positron emission tomography ([¹⁸F]FDG-PET), is considered a biomarker of AD-related neurodegeneration. This recent … Read more

GFAP in plasma and CSF in Down syndrome and Alzheimer’s disease

by
gfap - Sant Pau Memory Unit - Montoliu-Gaia - Alcolea

Alzheimer’s Disease, Down Syndrome and GFAP People with Down syndrome are at higher risk of developing Alzheimer’s disease than the general population. In fact, by the age of 70, more than 95% of people with Down syndrome will develop Alzheimer’s disease, which is the leading cause of death in this population. This strong association is … Read more

Concordance between amyloid markers in CSF

by
Delaby Sant Pau Memory Unit - Barcelona

Amyloid peptides and tau markers in CSF Cerebrospinal fluid (CSF) biomarkers of Alzheimer’s disease (AD), such as β-amyloid 1-42 (Aβ1-42), total tau (tTau) and pTau181, have improved the management of patients with cognitive impairment. Although Aβ1-42 is considered a marker of amyloid pathology, a series of studies have shown that a decrease in CSF Aβ1-42 … Read more

GFAP in blood helps predict the evolution of frontotemporal dementia

by

GFAP and frontotemporal dementia Frontotemporal dementia is a heterogeneous entity with variable clinical manifestations. As a consequence, it can be confused with psychiatric diseases or other neurodegenerative diseases such as Alzheimer’s disease. Despite the advances in the diagnosis of frontotemporal dementia in the last two decades, we still do not have a precise marker for … Read more

New plasma biomarker to detect Alzheimer’s disease in Down syndrome individuals

by
Down Alzheimer - Plasma Markers - APOE

Plasma biomarkers Scientists worldwide are immersed in the race for accurate, non-invasive and accessible biomarkers to detect and diagnose Alzheimer’s Disease. To date, major scientific advances allowed the identification of several biomarkers in cerebrospinal fluid or using positron emission tomography (PET). Yet, these methods are either invasive or expensive and not easily accessible to all … Read more

Blood biomarkers are useful to detect Alzheimer’s disease

by
Marcadores Sangre - Alcolea - JNNP - Sant Pau Memory Unit

Blood biomarkers for Alzheimer’s disease Recent developments in blood markers have made possible to track the different pathophysiological processes that occur in Alzheimer’s disease through plasma analysis. Our study “Use of plasma biomarkers for AT (N) classification of neurodegenerative dementias” evaluates three of these markers and has recently been published in the Journal of Neurology, … Read more